EUVIMEDEUVIMED entdecken
Crossref

Prevalence and Phenotypic Susceptibility to Doravirine of the HIV-1 Reverse Transcriptase V106I Polymorphism in B and Non-B Subtypes

Federica Giammarino, Adolfo de Salazar iD, Isabelle Malet, Laura Viñuela, Ana Fuentes iD, Francesco Saladini iD, Niccolò Bartolini, Charlotte Charpentier, Sidonie Lambert-Niclot iD, Gaetana Sterrantino iD, Maria Grazia Colao, Valeria Micheli und 14 weitere

The Journal of Infectious Diseases · 2024

DOI: 10.1093/infdis/jiae010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Federica Giammarino und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biotechnologies, University of Siena, Siena, Italy. Hauptthemen laut MEDLINE: HIV-1, HIV Reverse Transcriptase, HIV Infections, Pyridones. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Merck Sharp and Dohme, LLC, Plan Nacional de I + D + I, Fondo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Limited data are available regarding the susceptibility of the reverse transcriptase V106 polymorphism to doravirine.

Methods

Doravirine susceptibility was measured in site-directed mutants (SDMs) containing V106I, V106A, V106M, and Y188L mutations in subtype B (NL4-3, HXB2) and CRF02_AG background and in recombinant viruses with RT harboring V106I alone derived from 50 people with HIV.

Results

HIV-1 B subtype was detected in 1523 of 2705 cases. Prevalence of V106I was 3.2% in B and 2.5% in non-B subtypes, and was higher in subtype F (8.1%) and D (14.3%). Fold-changes (FC) in susceptibility for SDMs were below doravirine biological cutoff (3.0) for V106I, but not for V106A, V106M, and Y188L. Clinically derived viruses tested included 22 B (median FC, 1.2; interquartile range [IQR], 0.9–1.6) and 28 non-B subtypes (median FC, 1.8; IQR, 0.9–3.0). Nine (18%) viruses showed FC values equal or higher than the doravirine biological FC cutoff.

Conclusions

The prevalence of the HIV-1 RT V106I polymorphism in MeditRes HIV consortium remains low, but significantly more prevalent in subtypes D and F. V106I minimally decreased the susceptibility to doravirine in SDMs and most clinical isolates. Reduced susceptibility seems to occur at increased frequency in subtype F1; however, the clinical impact remains to be investigated. Clinical Trials Registration NCT04894357.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1HIV Reverse TranscriptaseHIV InfectionsPyridonesDrug Resistance, ViralAnti-HIV AgentsTriazolesHumansPolymorphism, GeneticPrevalenceMaleFemaleReverse Transcriptase InhibitorsAdultGenotypePhenotypeMiddle Aged

Stichwörter der Autor:innen

HIVV106Idoravirineresistance

Substanzen

HIV Reverse TranscriptasedoravirinePyridonesreverse transcriptase, Human immunodeficiency virus 1Anti-HIV AgentsTriazolesReverse Transcriptase Inhibitors

Autor:innen und Institutionen

  • Department of Medical Biotechnologies, University of Siena, Siena, Italy.
  • Clinical Microbiology, Hospital Universitario Clinico San Cecilio, Granada, Spain.
  • Instituto de Investigación Biosanitaria (ibs.Granada), Granada, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Laboratoire de Virologie, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
  • Service de Virologie, Université Paris Cité, INSERM, IAME, UMR 1137, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris, France.

ORCID-Profile: Adolfo de Salazar, Ana Fuentes, Francesco Saladini, Sidonie Lambert-Niclot, Gaetana Sterrantino, Rafael Delgado, Iker Falces-Romero, Dimitrios Paraskevis, Federico García

Förderung

  • Merck Sharp and Dohme, LLC
  • Plan Nacional de I + D + I
  • Fondo
  • Europeo de Desarrollo Regional
  • Fundacion Progreso y Salud
  • Junta de Andalucia
  • Instituto de Salud Carlos III

Zitieren

APA

Giammarino, F., de Salazar, A., Malet, I., Viñuela, L., Fuentes, A., Saladini, F., Bartolini, N., Charpentier, C., Lambert-Niclot, S., Sterrantino, G., Colao, M. G., Micheli, V., Bertoli, A., Fabeni, L., Teyssou, E., Delgado, R., Falces-Romero, I., Aguilera, A., Gomes, P., …, & García, F. (2024). Prevalence and Phenotypic Susceptibility to Doravirine of the HIV-1 Reverse Transcriptase V106I Polymorphism in B and Non-B Subtypes. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae010

Vancouver

Giammarino F, de Salazar A, Malet I, Viñuela L, Fuentes A, Saladini F, et al. Prevalence and Phenotypic Susceptibility to Doravirine of the HIV-1 Reverse Transcriptase V106I Polymorphism in B and Non-B Subtypes. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae010

BibTeX
@article{Giammarino2024,
  author = {Giammarino, Federica and de Salazar, Adolfo and Malet, Isabelle and Viñuela, Laura and Fuentes, Ana and Saladini, Francesco and Bartolini, Niccolò and Charpentier, Charlotte and Lambert-Niclot, Sidonie and Sterrantino, Gaetana and Colao, Maria Grazia and Micheli, Valeria and Bertoli, Ada and Fabeni, Lavinia and Teyssou, Elisa and Delgado, Rafael and Falces-Romero, Iker and Aguilera, Antonio and Gomes, Perpetua and Paraskevis, Dimitrios and Santoro, Maria M and Ceccherini-Silberstein, Francesca and Marcelin, Anne-Genevieve and Moreno, Cristina and Zazzi, Maurizio and García, Federico},
  title = {Prevalence and Phenotypic Susceptibility to Doravirine of the HIV-1 Reverse Transcriptase V106I Polymorphism in B and Non-B Subtypes},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  doi = {10.1093/infdis/jiae010}
}
Kostenlos starten →